Broncho-Vaxom is under clinical development by OM Pharma and currently in Phase I for Allergic Asthma. According to GlobalData, Phase I drugs for Allergic Asthma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Broncho-Vaxom’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Broncho-Vaxom overview
Bacterial lysate [Staphylococcus aureus + Streptococcus pyogenes + Streptococcus viridians + Klebsiella pneumonia + Klebsiella ozaenae + Haemophilus influenzae B + Neisseria catarrhalis + Diplococcus pneumonia] vaccine (Broncho-Vaxom) is a oral vaccine preparation, acts as an immunomodulating agent. It is formulated as capsules and granule for sublingual route of administration and inhalation route. Broncho-Vaxom is indicated for prophylaxis of recurrent respiratory tract infections and acute infectious exacerbations of chronic bronchitis. recurrent infections of the upper and lower respiratory tract, in particular due to chronic respiratory diseases (such as bronchitis, sinusitis).
OM-85 is under development for the treatment of recurrent wheezing, allergic asthma and viral infections. It was also under development for the treatment of atopic dermatitis.
OM Pharma overview
OM Pharma, a subsidiary of Optimus Holding Ltd, is a biopharmaceutical company. The company carries out manufacturing of medicines for the treatment of vascular diseases and prevention of urinary tract and respiratory infections. It focuses on developing immunotherapeutic products derived from microorganisms to treat viral and inflammatory-induced acute and chronic immune disorders. The company’s products include Broncho-Vaxom, which treats respiratory tract infections and Uro-Vaxom for urinary tract infections. Its Doxium targets microangiopathies, signs of chronic venous insufficiency in the lower limbs and hemorrhoidal syndrome. OM Pharma’s Doxiproct and Doxiproct Plus treats hemorrhoidal syndrome and Dicynone for capillary hemorrhages of different origin such as heavy menstrual bleeding, metrorrhagia, surgery affecting highly vascularized tissues, epistaxis and periventricular hemorrhage in newborns. It operates worldwide through an established international network of partners. OM Pharma is headquartered in Geneva, Genf, Switzerland.
For a complete picture of Broncho-Vaxom’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
